HIV-1 共受体的肽和蛋白质抑制剂。
Peptide and protein-based inhibitors of HIV-1 co-receptors.
机构信息
Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.
出版信息
Exp Biol Med (Maywood). 2013 May;238(5):442-9. doi: 10.1177/1535370213480696.
Abstract
Human immunodeficiency virus (HIV) afflicts an estimated 30 million people globally, making it a continuing pandemic. Despite major research efforts, the rate of new infections has remained relatively static over time. This article reviews an emerging strategy for the treatment of HIV, the inhibition of the co-receptors necessary for HIV entry, CCR5 and CXCR4. The aim of this article is to highlight potential therapeutics derived from peptides and proteins that show particular promise in HIV treatment. Molecules that act on CCR5, CXCR4 or on both receptors will be discussed herein.
摘要
人类免疫缺陷病毒（HIV）估计在全球范围内影响了 3000 万人，使其成为持续的大流行病。尽管进行了重大的研究努力，但新感染的速度随着时间的推移一直保持相对稳定。本文综述了一种新兴的 HIV 治疗策略，即抑制 HIV 进入所需的辅助受体 CCR5 和 CXCR4。本文的目的是强调从在 HIV 治疗中显示出特殊前景的肽和蛋白质中获得的潜在治疗剂。本文将讨论作用于 CCR5、CXCR4 或这两种受体的分子。
相似文献
1
Peptide and protein-based inhibitors of HIV-1 co-receptors.HIV-1 共受体的肽和蛋白质抑制剂。
Exp Biol Med (Maywood). 2013 May;238(5):442-9. doi: 10.1177/1535370213480696.
2
Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.HIV-1亚型和嗜性对趋化因子共受体进入抑制剂治疗的影响；病毒进入抑制概述。
Crit Rev Microbiol. 2015;41(4):473-87. doi: 10.3109/1040841X.2013.867829. Epub 2014 Mar 17.
3
[Viral entry as therapeutic target. Current situation of entry inhibitors].[以病毒进入为治疗靶点。进入抑制剂的现状]
Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 11:5-11. doi: 10.1016/s0213-005x(08)76557-1.
4
Function-oriented development of CXCR4 antagonists as selective human immunodeficiency virus (HIV)-1 entry inhibitors.作为选择性人类免疫缺陷病毒（HIV）-1进入抑制剂的CXCR4拮抗剂的功能导向开发。
J Med Chem. 2015 Feb 12;58(3):1452-65. doi: 10.1021/jm501772w. Epub 2015 Jan 28.
5
Targeting CXCR4 in HIV cell-entry inhibition.靶向 CXCR4 抑制 HIV 细胞进入。
Mini Rev Med Chem. 2009 Dec;9(14):1605-21. doi: 10.2174/138955709791012265.
6
HIV co-receptor drugs on the horizon.艾滋病病毒共受体药物即将问世。
GMHC Treat Issues. 2004 Jul-Aug;18(7-8):7-8.
7
Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides.靶向动态超分子机制的抗HIV药物研发：基于CXCR4/CCR5拮抗剂和gp41-C34重塑肽的进入和融合抑制剂
Curr HIV Res. 2005 Oct;3(4):289-301. doi: 10.2174/157016205774370429.
8
A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.一种能够抑制 CCR5 和 CXCR4 嗜性的人免疫缺陷病毒 1 型的低分子量进入抑制剂，作用于 gp41 的一个新靶点。
J Virol. 2010 Jul;84(14):7288-99. doi: 10.1128/JVI.00535-10. Epub 2010 Apr 28.
9
HIV-1 Entry Inhibitors: A Review of Experimental and Computational Studies.HIV-1进入抑制剂：实验与计算研究综述
Chem Biodivers. 2018 Oct;15(10):e1800159. doi: 10.1002/cbdv.201800159. Epub 2018 Sep 21.
10
Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1.关闭病毒进入的两扇门：HIV-1共受体与融合抑制剂的分子内结合
Virol J. 2008 May 1;5:56. doi: 10.1186/1743-422X-5-56.
引用本文的文献
1
Strategic Approaches to Improvise Peptide Drugs as Next Generation Therapeutics.将肽类药物改进为下一代治疗药物的策略方法。
Int J Pept Res Ther. 2023;29(4):61. doi: 10.1007/s10989-023-10524-3. Epub 2023 May 24.
2
Novel small synthetic HIV-1 V3 crown variants: CCR5 targeting ligands.新型小合成 HIV-1 V3 冠变异体：靶向 CCR5 的配体。
J Biochem. 2022 Sep 5;172(3):149-164. doi: 10.1093/jb/mvac052.
3
Development of peptide inhibitors of HIV transmission.HIV传播肽抑制剂的研发。
Bioact Mater. 2016 Sep 16;1(2):109-121. doi: 10.1016/j.bioactmat.2016.09.004. eCollection 2016 Dec.
4
Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity.发现并鉴定一种具有强效抗 HIV 活性的新型 CD4 结合连接子。
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00508-17. Print 2017 Aug.
5
Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications.乙型肝炎病毒和丁型肝炎病毒进入肝细胞：基本见解与临床意义。
J Hepatol. 2016 Apr;64(1 Suppl):S32-S40. doi: 10.1016/j.jhep.2016.02.011.
6
Using glycosaminoglycan/chemokine interactions for the long-term delivery of 5P12-RANTES in HIV prevention.利用糖胺聚糖/趋化因子相互作用实现 5P12-RANTES 在 HIV 预防中的长效递送。
Mol Pharm. 2013 Oct 7;10(10):3564-73. doi: 10.1021/mp3007242. Epub 2013 Aug 26.
本文引用的文献
1
Potent CXCR4 antagonists containing amidine type Peptide bond isosteres.含有脒型肽键电子等排体的强效CXCR4拮抗剂。
ACS Med Chem Lett. 2011 Mar 28;2(6):477-80. doi: 10.1021/ml200047e. eCollection 2011 Jun 9.
2
HIV-1 entry inhibitors: recent development and clinical use.HIV-1 进入抑制剂：最新进展与临床应用。
Curr Opin Virol. 2013 Feb;3(1):51-7. doi: 10.1016/j.coviro.2012.12.002. Epub 2013 Jan 3.
3
Enhancement of anti-HIV-1 activity by hot spot evolution of RANTES-derived peptides.通过RANTES衍生肽的热点进化增强抗HIV-1活性。
Chem Biol. 2012 Dec 21;19(12):1579-88. doi: 10.1016/j.chembiol.2012.10.007.
4
Design of a novel cyclotide-based CXCR4 antagonist with anti-human immunodeficiency virus (HIV)-1 activity.基于环肽的新型 CXCR4 拮抗剂的设计及其抗人免疫缺陷病毒（HIV-1）活性。
J Med Chem. 2012 Dec 13;55(23):10729-34. doi: 10.1021/jm301468k. Epub 2012 Nov 27.
5
Impact of the CXCR4 structure on docking-based virtual screening of HIV entry inhibitors.CXCR4 结构对基于对接的 HIV 进入抑制剂虚拟筛选的影响。
J Mol Graph Model. 2012 Sep;38:123-36. doi: 10.1016/j.jmgm.2012.06.010. Epub 2012 Jul 3.
6
CCR5 mutations distinguish N-terminal modifications of RANTES (CCL5) with agonist versus antagonist activity.CCR5 突变区分 RANTES（CCL5）的 N 端修饰具有激动剂与拮抗剂活性。
J Virol. 2012 Sep;86(18):10218-20. doi: 10.1128/JVI.00353-12. Epub 2012 Jul 11.
7
A conformationally frozen peptoid boosts CXCR4 affinity and anti-HIV activity.一种构象固定的类肽增强了CXCR4亲和力和抗HIV活性。
Angew Chem Int Ed Engl. 2012 Aug 6;51(32):8110-3. doi: 10.1002/anie.201202090. Epub 2012 Jul 3.
8
Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4-FC131 interactions.环五肽 CXCR4 拮抗剂的分子建模研究：CXCR4-FC131 相互作用的新见解。
Bioorg Med Chem Lett. 2012 Mar 15;22(6):2146-50. doi: 10.1016/j.bmcl.2012.01.134. Epub 2012 Feb 8.
9
Past, present, and future of entry inhibitors as HIV microbicides.作为HIV杀微生物剂的进入抑制剂的过去、现在与未来。
Curr HIV Res. 2012 Jan 1;10(1):19-26. doi: 10.2174/157016212799304616.
10
Study on CCR5 analogs and affinity peptides.CCR5 类似物和亲和肽研究。
Protein Eng Des Sel. 2012 Mar;25(3):97-105. doi: 10.1093/protein/gzr062. Epub 2012 Jan 11.
Zotero 插件